Efikasnost gubitka težine i sigurnost tirzepatida: Sistematski pregled.
PloS one
Sažetak istraživanja
Cilj Tirzeptid je novi glukagon-sličan peptid-1 receptor (GLP-1) i insulinotropni polipeptid (GIP) zavisan od glukoze, koji pokazuje dobru efikasnost za gubitak težine. Stoga, cilj nam je da istražimo efikasnost i sigurnost tirzepatida za gubitak težine kod pacijenata sa dijabetesom melitusom tipa 2 (T2DM) i gojaznih pacijenata u ovoj studiji meta-analize.
Metode Cochrane Library, PubMed, Embase, Clinical Trials i Web of Science pretražene su od početka do 5. oktobra 2022. Uključena su sva randomizirana kontrolirana ispitivanja (RCT). Odnos šanse (OR) izračunat je korištenjem modela s fiksnim ili slučajnim efektima pomoću softvera Review Manager 5.3.
Rezultati Ukupno je identifikovano deset studija (12 izveštaja) koje su uključivale 9.873 pacijenata. Značajan gubitak tjelesne težine u grupi koja je primala tirzepatid u odnosu na placebo za -9,81 kg (95% CI (-12,09, -7,52), GLP-1 RA za -1,05 kg (95% CI (-1,48, -0,63) i inzulina za -1,93 kg), (95% CI, -1,81, respektivno). tjelesna težina pacijenata je značajno smanjena u tri doze tirzepatida (5 mg, 10 mg i 15 mg) u poređenju sa onima koji su primali placebo/GLP-1 RA/insulin Neželjeni događaji (uključujući dijareju, mučninu, povraćanje i smanjen apetit) tirzepatida bili su veći od onih kod placeba/bazalnog inzulina, ali su slični GLP-1 RA Zaključak.
Prikaži originalni naslov i sažetak na engleskom
Weight loss efficiency and safety of tirzepatide: A Systematic review.
Objective Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2DM) and obesity patients in this meta-analysis study.
Methods Cochrane Library, PubMed, Embase, Clinical Trials, and Web of Science were searched from inception to October 5, 2022. All randomized controlled trials (RCTs) were included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software.
Results In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively. In sub-analysis, the body weight of patients was significantly reduced in three tirzepatide doses (5 mg, 10 mg, and 15 mg) when compared with those of the placebo/GLP-1 RA/insulin. In terms of safety, the incidence of any adverse events and adverse events leading to study drug discontinuation was higher in the tirzepatide group, but the incidence of serious adverse events and hypoglycaemia was lower. Additionally, the gastrointestinal adverse events (including diarrhea, nausea, vomiting and decreased appetite) of tirzepatide were higher than those of placebo/basal insulin, but similar to GLP-1 RAs.
Conclusion In conclusion, tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction.
Izvorni podaci
- DOI
- 10.1371/journal.pone.0285197
- PMID
- 37141329
- PMCID
- PMC10159347
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom